DMD antisense oligonucleotide exon skipping therapy (Entrada Therapeutics)

N/A

Report date: 2025/03/14 16:27:07

Base Information

Drug NameDMD antisense oligonucleotide exon skipping therapy (Entrada Therapeutics)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionDMD gene modulators
TargetsDystrophin
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEntrada Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEntrada Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophy, Duchenne
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A